» Articles » PMID: 16973228

Tumor Lactate Content Predicts for Response to Fractionated Irradiation of Human Squamous Cell Carcinomas in Nude Mice

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2006 Sep 16
PMID 16973228
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: The present study was performed to test the hypothesis that lactate accumulation correlates with the radioresistance of malignant tumors due to the radical scavenging capacity of lactate or metabolic intermediates of glycolysis, such as pyruvate.

Materials And Methods: Five human head and neck squamous cell carcinoma cell lines (HNSCCs) xenografted in nude mice were treated with a clinically relevant irradiation protocol with 30 fractions within 6 weeks. The radiation dose necessary to locally control 50% of the tumors (TCD50) ranged from 47.4 to 129.8 Gy. Concentrations of glucose, lactate, and ATP in viable tumor regions as potential indicators of glycolytic activity were assessed with structure-associated quantitative bioluminescence imaging.

Results: Mean lactate concentrations of the different tumor cell lines were in the range of 7.3-25.9 micromol/g. TCD50 values were positively correlated with tumor lactate levels (R = 0.9824, p = 0.0028).

Conclusions: The data obtained support the hypothesis that tissue lactate content correlates with radioresistance in solid human tumors. Furthermore, the results suggest that tumor lactate content determined non-invasively by proton magnetic resonance spectroscopy imaging may be used to predict for radioresistance of malignancies in the clinic; the data also imply that transient inhibition of glycolysis during treatment might possibly sensitize tumors to irradiation.

Citing Articles

Lactate in skin homeostasis: metabolism, skin barrier, and immunomodulation.

Ruan D, Hu T, Yang X, Mo X, Ju Q Front Immunol. 2025; 16:1510559.

PMID: 40046050 PMC: 11879785. DOI: 10.3389/fimmu.2025.1510559.


Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors.

Gurel Z, Luy M, Luo Q, Arp N, Erbe A, Kesarwala A Front Oncol. 2024; 14:1428802.

PMID: 39435293 PMC: 11491500. DOI: 10.3389/fonc.2024.1428802.


Deuterium MR spectroscopy: potential applications in oncology research.

Bitencourt A, Bhowmik A, Marcal Filho E, Gullo R, Mazaheri Y, Kapetas P BJR Open. 2024; 6(1):tzae019.

PMID: 39165295 PMC: 11333568. DOI: 10.1093/bjro/tzae019.


Moving from conventional to adaptive risk stratification for oropharyngeal cancer.

Sandulache V, Kirby R, Lai S Front Oncol. 2024; 14:1287010.

PMID: 38549938 PMC: 10972883. DOI: 10.3389/fonc.2024.1287010.


Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.